Leaders in Life Science Recruitment

Interim Management

Increasingly, the industry is realising the value of retaining highly experienced professionals on a short-term basis as interim managers. Such candidates are often required to hit the ground running while a permanent recruitment cycle unfolds. Alternatively they may be needed for a project-specific assignment to provide specialist skills that do not exist within the organisation.

The value that an interim manager can bring to a company on a short term assignment cannot be over-estimated and more and more organisations are realising this.

Talentmark provides interim managers in areas such as:

  • Regulatory Affairs
  • General Management
  • Marketing
  • Pharmacovigilance  
  • Medical Advisers
  • Business Development and Commercial Management
  • Medical Information
  • Health Economics
  • Pricing
  • PR and Communications
  • Manufacturing, Supply Chain and Logistics
  • Specialist NED's
  • HR

Companies can access experienced specialists who will effectively function as 'turn-key' providers of business solutions from day one.

Talentmark has a successful 40 year history of providing a portfolio of recruitment solutions across the pharma, biotech and healthcare sectors.  As a result, we are one of very few organisations that can fully understand and provide candidates who best suit challenging interim assignments.

Consequently our reputation is based on the philosophy of being able to supply the right Interim Managers, as opposed to endless lists of unsuitable candidates. As a result, our relationship with our talent pool is as important as the relationship we we have with our clients.

To source some of the industry's best interim managers, please contact us, or alternatively, please register your details as a candidate.

Current Opportunities


Browse

Industry News

Novartis gets fresh EU approval for 'under-appreciated' Galvus
Novartis gets fresh EU approval for 'under-appreciated' Galvus ...

GSK halts trials of antibiotic, expands Australian site
GSK halts trials of antibiotic, expands Australian site...

B-MS' Inhibitex buy moves closer; HCV news from Gilead, Idenix
B-MS' Inhibitex buy moves closer; HCV news from Gilead, Idenix...

Clinuvel files treatment for rare skin disease with EMA
Clinuvel files treatment for rare skin disease with EMA ...

US pharma: 54 drugs for COPD now in R&D
US pharma: 54 drugs for COPD now in R&D...